[1] Sakurai H, Ishikawa H, Okumura T.  Proton beam therapy in Japan: current and future status[J]. Jpn J Clin Oncol, 2016, 46(10): 885-892.   doi: 10.1093/jjco/hyw102
[2] Wilson RR.  Radiological Use of Fast Protons[J]. Radiology, 1946, 47(5): 487-491.   doi: 10.1148/47.5.487
[3] Tobias CA, Lawrence JH, Born JL, et al.  Pituitary Irradiation with High-Energy Proton Beams A Preliminary Report[J]. Cancer Res, 1958, 18(2): 121-134.
[4] 田素青, 王俊杰..  医用小型激光质子加速器在肿瘤治疗中的研究进展[J]. 癌症进展, 2018, 16(8): 932-934.   doi: 10.11877/j.issn.1672-1535.2018.16.08.02
Tian SQ, Wang JJ..  Research progress of small medical laser proton accelerator in cancer treatment[J]. Oncology Progress, 2018, 16(8): 932-934.   doi: 10.11877/j.issn.1672-1535.2018.16.08.02
[5] Szeto YZ, Witte MG, van Kranen SR, et al.  Effects of anatomical changes on pencil beam scanning proton plans in locally advanced nsclc patients[J]. Radiother Oncol, 2016, 120(2): 286-292.   doi: 10.1016/j.radonc.2016.04.002
[6] Jäkel O, Smith AR, Orton CG.  The more important heavy charged particle radiotherapy of the future is more likely to be with heavy ions rather than protons[J]. Med Phys, 2013, 40(9): 090601-.   doi: 10.1118/1.4798945
[7] Brada M, Bortfeld T.  Proton Therapy: The Present and the Future[J]. Semin Radiat Oncol, 2013, 23(2): 75-76.   doi: 10.1016/j.semradonc.2012.11.001
[8] Olive PL.  DNA damage and repair in individual cells: applications of the comet assay in radiobiology[J]. Int J Radiat Biol, 1999, 75(4): 395-405.   doi: 10.1080/095530099140311
[9]

Giovannini G, Böhlen T, Cabal G, et al. Variable rbe in proton therapy: comparison of different model predictions and their influence on clinical-like scenarios[J/OL]. Radiat Oncol, 2016, 11: 68[2019-01-05]. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-016-0642-6. DOI: 10.1186/s13014−016−0642−6.
[10] Cotter SE, Mcbride SM, Yock TI.  Proton radiotherapy for solid tumors of childhood[J]. Technol Cancer Res Treat, 2012, 11(3): 267-278.   doi: 10.7785/tcrt.2012.500295
[11] Weber DC, Lomax AJ, Rutz HP, et al.  Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas[J]. Radiother Oncol, 2004, 71(3): 251-258.   doi: 10.1016/j.radonc.2004.02.011
[12] Frank SJ, Cox JD, Gillin M, et al.  Multifield Optimization Intensity Modulated Proton Therapy For Head and Neck Tumors: A Translation to Practice[J]. Int J Radiat Oncol Biol Phys, 2014, 89(4): 846-853.   doi: 10.1016/j.ijrobp.2014.04.019
[13] Colevas AD, Yom SS, Pfister DG, et al.  NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018[J]. J Natl Compr Canc Netw, 2018, 16(5): 479-490.   doi: 10.6004/jnccn.2018.0026
[14] Chang JY, Zhang XD, Knopf A, et al.  Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee[J]. Int J Radiat Oncol Biol Phys, 2017, 99(1): 41-50.   doi: 10.1016/j.ijrobp.2017.05.014
[15] Benson III AB, D'Angelica MI, Abbott DE, et al.  NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017[J]. J Natl Compr Canc Netw, 2017, 15(5): 563-573.   doi: 10.6004/jnccn.2017.0059
[16] Zenda S, Akimoto T, Mizumoto M, et al.  Phase Ⅱ study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses[J]. Radiother Oncol, 2016, 118(2): 267-271.   doi: 10.1016/j.radonc.2015.10.025
[17] Seibel I, Riechardt AI, Heufelder J, et al.  Adjuvant ab interno tumor treatment after proton beam irradiation[J]. Am J Ophthalmol, 2017, 178: 94-100.   doi: 10.1016/j.ajo.2017.03.027
[18]

Moriarty JP, Borah BJ, Foote RL, et al. Cost-Effectiveness of Proton Beam Therapy for Intraocular Melanoma[J/OL]. PLoS One, 2015, 10(5): e0127814[2019-01-05]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0127814. DOI: 10.1371/journal.pone.0127814.
[19] Wenkel E, Thornton AF, Finkelstein D, et al.  Benign meningioma: Partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2000, 48(5): 1363-1370.   doi: 10.1016/S0360-3016(00)01411-5
[20] Weber DC, Schneider R, Goitein G, et al.  Spot Scanning-Based Proton Therapy for Intracranial Meningioma: Long-Term Results From the Paul Scherrer Institute[J]. Int J Radiat Oncol Biol Phys, 2012, 83(3): 865-871.   doi: 10.1016/j.ijrobp.2011.08.027
[21] Goldbrunner R, Minniti G, Preusser M, et al.  Eano guidelines for the diagnosis and treatment of meningiomas[J]. Lancet Oncol, 2016, 17(9): E383-E391.   doi: 10.1016/S1470-2045(16)30321-7
[22] Allen AM, Pawlicki T, Dong L, et al.  An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee[J]. Radiother Oncol, 2012, 103(1): 8-11.   doi: 10.1016/j.radonc.2012.02.001
[23] Ahmed KA, Demetriou SK, McDonald M, et al.  Clinical benefits of proton beam therapy for tumors of the skull base[J]. Cancer Control, 2016, 23(3): 213-219.   doi: 10.1177/107327481602300304
[24] Holliday EB, Frank SJ.  Proton Radiation Therapy for Head and Neck Cancer: A Review of the Clinical Experience to Date[J]. Int J Radiat Oncol Biol Phys, 2014, 89(2): 292-302.   doi: 10.1016/j.ijrobp.2014.02.029
[25] Berman AT, James SS, Rengan R.  Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions[J]. Cancers (Basel), 2015, 7(3): 1178-1190.   doi: 10.3390/cancers7030831
[26] Chang JY, Komaki R, Lu C, et al.  Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage Ⅲ nonsmall cell lung cancer[J]. Cancer, 2011, 117(20): 4707-4713.   doi: 10.1002/cncr.26080
[27] Oshiro Y, Okumura T, Kurishima K, et al.  High-dose concurrent chemo-proton therapy for Stage Ⅲ NSCLC: Preliminary results of a Phase Ⅱ study[J]. J Radiat Res, 2014, 55(5): 959-965.   doi: 10.1093/jrr/rru034
[28] Nguyen QN, Ly NB, Komaki R, et al.  Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage Ⅱ-Ⅲ inoperable non-small cell lung cancer[J]. Radiother Oncol, 2015, 115(3): 367-372.   doi: 10.1016/j.radonc.2015.05.014
[29]

Zschaeck S, Simon M, Löck S, et al. PRONTOX-proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial[J/OL]. Trials, 2016, 17(1): 543[2019-01-05]. https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1679-4. DOI: 10.1186/s13063−016−1679−4.
[30] McAvoy SA, Ciura KT, Rineer JM, et al.  Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer[J]. Radiother Oncol, 2013, 109(1): 38-44.   doi: 10.1016/j.radonc.2013.08.014
[31] Seco J, Gu G, Marcelos T, et al.  Proton Arc Reduces Range Uncertainty Effects and Improves Conformality Compared With Photon Volumetric Modulated Arc Therapy in Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer[J]. Int J Radiat Oncol Biol Phys, 2013, 87(1): 188-194.   doi: 10.1016/j.ijrobp.2013.04.048
[32] Chang JY, Li H, Zhu XR, et al.  Clinical Implementation of Intensity Modulated Proton Therapy for Thoracic Malignancies[J]. Int J Radiat Oncol Biol Phys, 2014, 90(4): 809-818.   doi: 10.1016/j.ijrobp.2014.07.045
[33] Chuong MD, Hallemeier CL, Jabbour SK, et al.  Improving Outcomes for Esophageal Cancer using Proton Beam Therapy[J]. Int J Radiat Oncol Biol Phys, 2016, 95(1): 488-497.   doi: 10.1016/j.ijrobp.2015.11.043
[34] Plastaras JP, Berman AT, Freedman GM.  Special Cases for Proton Beam Radiotherapy: Re-irradiation, Lymphoma, and Breast Cancer[J]. Semin Oncol, 2014, 41(6): 807-819.   doi: 10.1053/j.seminoncol.2014.10.001
[35] Reiazi R, Norozi A, Etedadialiabadi M.  A Literature Survey on Cost-Effectiveness of Proton Beam Therapy in the Management of Breast Cancer Patients[J]. Iran J Cancer Prev, 2015, 8(6): e4373-.   doi: 10.17795/ijcp-4373
[36] Bush DA, Do S, Lum S, et al.  Partial Breast Radiation Therapy With Proton Beam: 5-Year Results With Cosmetic Outcomes[J]. Int J Radiat Oncol Biol Phys, 2014, 90(3): 501-505.   doi: 10.1016/j.ijrobp.2014.05.1308
[37] Darby SC, Ewertz M, McGale P, et al.  Risk of Ischemic Heart Disease in Women After Radiotherapy for Breast Cancer[J]. N Engl J Med, 2013, 368(11): 987-998.   doi: 10.1056/NEJMoa1209825
[38] Durante M, Orecchia R, Loeffler JS.  Charged-particle therapy in cancer: clinical uses and future perspectives[J]. Nat Rev Clin Oncol, 2017, 14(8): 483-495.   doi: 10.1038/nrclinonc.2017.30
[39] Nakayama H, Sugahara S, Tokita M, et al.  Proton beam therapy for hepatocellular carcinoma: The University of Tsukuba experience[J]. Cancer, 2009, 115(23): 5499-5506.   doi: 10.1002/cncr.24619
[40] Bush DA, Kayali Z, Grove R, et al.  The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial[J]. Cancer, 2011, 117(13): 3053-3059.   doi: 10.1002/cncr.25809
[41] Oshiro Y, Mizumoto M, Okumura T, et al.  Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma[J]. Radiother Oncol, 2017, 123(2): 240-245.   doi: 10.1016/j.radonc.2017.03.004
[42] Qi WX, Fu S, Zhang Q, et al.  Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: A systematic review and meta-analysis[J]. Radiother Oncol, 2015, 114(3): 289-295.   doi: 10.1016/j.radonc.2014.11.033
[43] Terashima K, Demizu Y, Hashimoto N, et al.  A phase Ⅰ/Ⅱ study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis[J]. Radiother Oncol, 2012, 103(1): 25-31.   doi: 10.1016/j.radonc.2011.12.029
[44] Loehrer PJ Sr, Feng Y, Cardenes H, et al.  Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients with Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial[J]. J Clin Oncol, 2011, 29(31): 4105-4112.   doi: 10.1200/JCO.2011.34.8904
[45] Mahal BA, Chen YW, Efstathiou JA, et al.  National Trends and Determinants of Proton Therapy Use for Prostate Cancer: A National Cancer Data Base Study[J]. Cancer, 2016, 122(10): 1505-1512.   doi: 10.1002/cncr.29960
[46] Hoppe BS, Michalski JM, Mendenhall NP, et al.  Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer[J]. Cancer, 2014, 120(7): 1076-1082.   doi: 10.1002/cncr.28536
[47] Verma V, Mishra MV, Mehta MP.  A systematic review of the cost and cost-effectiveness studies of proton radiotherapy[J]. Cancer, 2016, 122(10): 1483-1501.   doi: 10.1002/cncr.29882
[48] Yock TI, Yeap BY, Ebb DH, et al.  Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: A phase 2 single-arm study[J]. Lancet Oncol, 2016, 17(3): 287-298.   doi: 10.1016/S1470-2045(15)00167-9
[49] Kahalley LS, Ris MD, Grosshans DR, et al.  Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain Tumors[J]. J Clin Oncol, 2016, 34(10): 1043-1049.   doi: 10.1200/JCO.2015.62.1383
[50] Greenberger BA, Pulsifer MB, Ebb DH, et al.  Clinical Outcomes and Late Endocrine, Neurocognitive, and Visual Profiles of Proton Radiation for Pediatric Low-Grade Gliomas[J]. Int J Radiat Oncol Biol Phys, 2014, 89(5): 1060-1068.   doi: 10.1016/j.ijrobp.2014.04.053
[51] Weber DC, Habrand JL, Hoppe BS, et al.  Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN[J]. Radiother Oncol, 2018, 128(1): 44-55.   doi: 10.1016/j.radonc.2018.05.020
[52] Bishop AJ, Greenfield B, Mahajan A, et al.  Proton Beam Therapy Versus Conformal Photon Radiation Therapy for Childhood Craniopharyngioma: Multi-Institutional Analysis of Outcomes, Cyst Dynamics, and Toxicity[J]. Int J Radiat Oncol Biol Phys, 2014, 90(2): 354-361.   doi: 10.1016/j.ijrobp.2014.05.051
[53] Weber DC, Ares C, Albertini F, et al.  Pencil Beam Scanning Proton Therapy for Pediatric Parameningeal Rhabdomyosarcomas: Clinical Outcome of Patients Treated at the Paul Scherrer Institute[J]. Pediatr Blood Cancer, 2016, 63(10): 1731-1736.   doi: 10.1002/pbc.25864
[54] Luu QT, Loredo LN, Archambeau JO, et al.  Fractionated Proton Radiation Treatment for Pediatric Craniopharyngioma: Preliminary Report[J]. Cancer J, 2006, 12(2): 155-159.
[55] Wolden SL, Lyden ER, Arndt CA, et al.  Local Control for Intermediate-Risk Rhabdomyosarcoma: Results from D9803 According to Histology, Group, Site, and Size: A Report from the Children's Oncology Group[J]. Int J Radiat Oncol Biol Phys, 2015, 93(5): 1071-1076.   doi: 10.1016/j.ijrobp.2015.08.040
[56] Koscielniak E, Feuchtgruber S, Sparber-Sauer M, et al.  Prognosis of patients with parameningeal rhabdomyosarcoma (PM-RMS): The long term results of five consecutive CWS studies 1981-2009[J]. J Clin Oncol, 2016, 34(15S): S10529-10529.   doi: 10.1200/JCO.2016.34.15_suppl.10529
[57] Leiser D, Calaminus G, Malyapa R, et al.  Tumour control and Quality of Life in children with rhabdomyosarcoma treated with pencil beam scanning proton therapy[J]. Radiother Oncol, 2016, 120(1): 163-168.   doi: 10.1016/j.radonc.2016.05.013
[58] Rombi B, DeLaney TF, MacDonald SM, et al.  Proton Radiotherapy for Pediatric Ewing's Sarcoma: Initial Clinical Outcomes[J]. Int J Radiat Oncol Biol Phys, 2012, 82(3): 1142-1148.   doi: 10.1016/j.ijrobp.2011.03.038
[59] Frisch S, Timmermann B.  The Evolving Role of Proton Beam Therapy for Sarcomas[J]. Clin Oncol, 2017, 29(8): 500-506.   doi: 10.1016/j.clon.2017.04.034
[60]

吉喆, 姜玉良. 质子放疗的临床应用研究进展[J]. 西部医学, 2016, 28(4): 580-584, 封三. DOI: 10.3969/j.issn.1672−3511.2016.04.036.

Ji Z, Jiang YL. Developments of clinical application of proton beam radiotherapy[J]. Med J West China, 2016, 28(4): 580-584, inside back cover. DOI: 10.3969/j.issn.1672−3511.2016.04.036.
[61] Bortfeld TR, Loeffler JS.  Three ways to make proton therapy affordable[J]. Nature, 2017, 549(7673): 451-453.   doi: 10.1038/549451a